Replies to post #201986 on Biotech Values

[DewDiligence]

RVNC—My post from one year ago (#msg-114249260):

I’m skeptical of RT001… I don’t think a topical product will work well in cosmetic applications.

If it were up to me, RVNC would drop RT001 completely and focus on RT002, the (long-acting) injected botulinum toxic that figures to be strong competition for Botox.

In other words, I’m ok with today’s decision to discontinue clinical development of RT001 and focus all resources on RT002.

Press release:
http://finance.yahoo.com/news/revance-reports-results-rt001-topical-200100770.html

CC at 4:30pm ET.